Quarterly report · Q3
9987.TEDINET S100STF5
Period2023-04-01 → 2023-12-31
Filed2024-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.81T | 2023-04-01 → 2023-12-31 | Cons. | Net sales |
| Revenue | ¥2.31T | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.76T | 2022-04-01 → 2022-12-31 | Cons. | Net sales |
| Operating income | ¥26.5bn | 2023-04-01 → 2023-12-31 | Cons. | Operating income |
| Operating income | ¥24.4bn | 2022-04-01 → 2022-12-31 | Cons. | Operating income |
| Ordinary income | ¥29.0bn | 2023-04-01 → 2023-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥36.4bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥27.3bn | 2022-04-01 → 2022-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥37.1bn | 2023-04-01 → 2023-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥27.0bn | 2022-04-01 → 2022-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥25.5bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥20.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥18.2bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥25.5bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss |
| Net income | ¥18.1bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss |
| Total assets | ¥1.30T | at 2023-12-31 | Cons. | Assets |
| Total assets | ¥1.15T | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥1.30T | at 2022-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥893.1bn | at 2023-12-31 | Cons. | Liabilities |
| Total liabilities | ¥734.6bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥411.1bn | at 2023-12-31 | Cons. | Net assets |
| Net assets / equity | ¥411.5bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥412.7bn | at 2022-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥178.6bn | at 2023-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥109.0bn | at 2023-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥310.3 | 2023-04-01 → 2023-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥118.63 | 2023-10-01 → 2023-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥236.47 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥208.46 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥85.55 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 31.5% | at 2023-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 35.9% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 31.6% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 40
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q3r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥73.4bn |
| jpcrp040300-q3r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥73.4bn |
| jpcrp040300-q3r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥12m |
| jpcrp040300-q3r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥1.1bn |
| jpcrp040300-q3r_E02780-000The Healthcare Product Development Businessreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥39.3bn |
| jpcrp040300-q3r_E02780-000The Healthcare Product Development Businessreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥8.8bn |
| jpcrp040300-q3r_E02780-000The Healthcare Product Development Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥30.4bn |
| jpcrp040300-q3r_E02780-000The Healthcare Product Development Businessreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥2.2bn |
| jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥199.3bn |
| jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥22.0bn |
| jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥177.3bn |
| jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥808m |
| jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥1.75T |
| jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥1.71T |
| jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥39.2bn |
| jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥22.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-12-31 | ¥2.06T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-12-31 | ¥1.81T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥247.0bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-12-31 | ¥26.6bn |
| jpcrp040300-q3r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥73.4bn |
| jpcrp040300-q3r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥73.4bn |
| jpcrp040300-q3r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥6m |
| jpcrp040300-q3r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥1.6bn |
| jpcrp040300-q3r_E02780-000The Healthcare Product Development Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥36.0bn |
| jpcrp040300-q3r_E02780-000The Healthcare Product Development Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥9.0bn |
| jpcrp040300-q3r_E02780-000The Healthcare Product Development Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥27.0bn |
| jpcrp040300-q3r_E02780-000The Healthcare Product Development Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥1.6bn |
| jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥161.0bn |
| jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥21.7bn |
| jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥139.3bn |
| jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥854m |
| jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥1.69T |
| jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥1.65T |
| jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥38.8bn |
| jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥20.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-12-31 | ¥1.96T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-12-31 | ¥1.76T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥205.1bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-12-31 | ¥24.3bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 354
| Item | Context | Value | Unit |
|---|---|---|---|
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Critical contracts for operation (text) | FilingDateInstant | Text · Plus | |
| Total number of shares (text) | FilingDateInstant | Text · Plus | |
| Issued shares total number of shares etc (text) | FilingDateInstant | Text · Plus | |
| Class issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)普通株式 | |
| Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)東京証券取引所プライム市場名古屋証券取引所プレミア市場札幌証券取引所 | |
| Description issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)単元株式数は 100株であります。 | |
| Details of employee share option program (text) | FilingDateInstant | Text · Plus | |
| Other information on share acquisition rights (text) | FilingDateInstant | Text · Plus | |
| Exercises etc of moving strike convertible bonds etc (text) | FilingDateInstant | Text · Plus | |
| Changes in number of issued shares stated capital etc (text) | FilingDateInstant | Text · Plus | |
| Major shareholders (text) | FilingDateInstant | Text · Plus | |
| Voting rights (text) | FilingDateInstant | Text · Plus | |
| Issued shares voting rights (text) | FilingDateInstant | Text · Plus | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | Original text (Japanese)単元株式数は100株であります。 | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | Original text (Japanese)同上 | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | － | |
| Treasury shares etc (text) | FilingDateInstant | Text · Plus | |
| Name of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)㈱スズケン | |
| Address of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)名古屋市東区東片端町８番地 | |
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYTDDuration | Text · Plus | |
| Note on independent audit financial information | CurrentYTDDuration | Text · Plus | |
| Quarterly consolidated balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of income (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of comprehensive income (text) | CurrentYTDDuration | Text · Plus | |
| Notes changes in scope of consolidation or equity method (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding promissory notes due on balance sheet date (text) | CurrentQuarterInstant | Text · Plus | |
| Description of fact that quarterly statement of cash flows has not been prepared (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Description of nature of differences between profit loss of reportable segments total and quarterly financial statements (text) | Prior1YTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1YTDDuration | Text · Plus | |
| Description of nature of differences between profit loss of reportable segments total and quarterly financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Disclosure of changes etc in reportable segments (text) | CurrentYTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |